# Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

> **NCT02758132** · PHASE2 · TERMINATED · sponsor: **University of Hawaii** · enrollment: 1 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Denosumab
- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02758132
- **Lead sponsor:** University of Hawaii
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-01
- **Primary completion:** 2016-09-06
- **Final completion:** 2016-09-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Low accruals
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02758132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02758132, "Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02758132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*